Literature DB >> 26439449

Role of radiation in the treatment of non-metastatic osseous Ewing sarcoma.

Matthew S Ning1, Stephanie M Perkins2, Scott C Borinstein3, Ginger E Holt4, Mark J Stavas1, Eric T Shinohara1.   

Abstract

INTRODUCTION: Local control, either with surgery, radiation (RT) or both, is essential in the management of localised Ewing sarcoma; however, the relative role of RT remains controversial.
METHODS: Using the Surveillance, Epidemiology, and End Results database, 612 patients treated for non-metastatic skeletal Ewing sarcoma between the years 1988 and 2010 were identified.
RESULTS: Median age and follow-up were 13 years (range: 0-21) and 56 months (range: 0-287), respectively. Five-year overall survival (OS) for the cohort was 74.4 ± 2.0%. Patients received surgery alone (51.3%), RT alone (21.6%) or both (27.1%). Patients with skeletal Ewing sarcoma had improved OS with surgery alone compared with other treatments. However, in subset analyses, RT was not inferior to surgery alone for appendicular (5-year OS: 80.0% vs. 79.3%), non-pelvic (84.3% vs. 79.9%) or localised disease (confined to cortex or periosteum; 79.7% vs. 80.6%). After controlling for stage and site, no increase in mortality was observed with RT versus surgery alone (hazard ratio = 0.77 (95% confidence interval: 0.49-1.19)).
CONCLUSIONS: In regard to survival, RT did not appear to be inferior to surgery alone for most patients, particularly those with disease at favourable sites (localised, appendicular, non-pelvic). In select patients with Ewing sarcoma, RT may be an appropriate strategy for local control that does not necessarily compromise survival outcomes.
© 2015 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  SEER program; paediatrics; secondary malignancy

Mesh:

Year:  2015        PMID: 26439449     DOI: 10.1111/1754-9485.12389

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  [18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma.

Authors:  Alessio Annovazzi; Virginia Ferraresi; Vincenzo Anelli; Renato Covello; Sabrina Vari; Carmine Zoccali; Roberto Biagini; Rosa Sciuto
Journal:  Eur Radiol       Date:  2021-03-13       Impact factor: 5.315

2.  A Comparison of Pediatric vs. Adult Patients with the Ewing Sarcoma Family of Tumors.

Authors:  Vivek Verma; Kyle A Denniston; Christopher J Lin; Chi Lin
Journal:  Front Oncol       Date:  2017-05-08       Impact factor: 6.244

3.  A Therapeutic Role for Survivin in Mitigating the Harmful Effects of Ionizing Radiation.

Authors:  Katherine H Carruthers; Gregory Metzger; Eugene Choi; Matthew J During; Ergun Kocak
Journal:  Sarcoma       Date:  2016-04-17

4.  Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92.

Authors:  Jeremy Whelan; Allan Hackshaw; Anne McTiernan; Robert Grimer; David Spooner; Jessica Bate; Andreas Ranft; Michael Paulussen; Herbert Juergens; Alan Craft; Ian Lewis
Journal:  Clin Sarcoma Res       Date:  2018-03-30

5.  Comparison of local control and survival outcomes between surgical and non-surgical local therapy on pelvic Ewing's sarcoma patients: a meta-analysis.

Authors:  Xianbiao Xie; Ziliang Zeng; Hao Yao; Qinglin Jin; Yiying Bian; Dongming Lv; Jian Tu; Bo Wang; Lili Wen; Jingnan Shen
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.